Effects of Latanoprost, Bimatoprost and Travoprost in Patients With Latanoprost-resistant Glaucoma
Status:
Unknown status
Trial end date:
2013-01-01
Target enrollment:
Participant gender:
Summary
Intraocular pressure (IOP) is considered to be the main risk factor for progression of
glaucoma and therefore the main target of therapy. Pharmacologic treatment of glaucoma has
changed considerably during the last decades due to the introduction of prostaglandin
analogues. Three of these are commonly used in North America: latanoprost (Latanoprost T,
Pfizer), Travoprost (Travatan TM, Alcon) and bimatoprost (Lumigan TM, Allergan).
There have been several studies to evaluate their effectiveness. The three seem to be
equivalent, according to the only study that has compared the molecules. Latanoprost is
employed initially, due to its paucity of side effects when compared to the other two
analogues. However, if it is not effective, several studies ahve shown that a result is
possible using either travoprost or bimatoprost. No study has been conducted to date
systematically comparing the three molecules in cases of resistance to latanoprost. In
actuality, the investigators patients will receive treatment identical to current practice
with the exception of the group continuing with latanoprost. Several studies confirm the
benefit of changing prostaglandin analogues if the first has not signficantly decreased the
IOP (Palmberg et al. 2004). Each prostaglandin has unique properties which may cause the
mechanism of action to vary slightly among patients. (cf. Pharmacological Aspects)
The goal of the study is thus to evaluate the efficaciousness of latanoprost, bimatoprost and
travoprost in their IOP-lowering capacity in patients who do not initially respond to
latanoprost.
Phase:
N/A
Details
Lead Sponsor:
Centre de recherche du Centre hospitalier universitaire de Sherbrooke